UBS Group Cuts Charles River Laboratories Intl. (NYSE:CRL) Price Target to $145.00

Charles River Laboratories Intl. (NYSE:CRL) had its price target lowered by research analysts at UBS Group from $147.00 to $145.00 in a research report issued on Thursday, November 7th, Stock Target Advisor reports. The firm presently has a “neutral” rating on the medical research company’s stock. UBS Group’s price target suggests a potential upside of 4.26% from the stock’s current price.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Other equities analysts have also recently issued reports about the stock. Bank of America cut shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price target on the stock. in a report on Friday, October 18th. Credit Suisse Group set a $138.00 price target on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a report on Friday, September 13th. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. SunTrust Banks lifted their price objective on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and a consensus price target of $150.50.

NYSE CRL traded up $1.48 on Thursday, hitting $139.07. 293,486 shares of the stock were exchanged, compared to its average volume of 356,343. Charles River Laboratories Intl. has a 52-week low of $103.00 and a 52-week high of $149.07. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.43 and a quick ratio of 1.20. The company has a market capitalization of $6.72 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 2.10 and a beta of 1.08. The company’s 50-day moving average price is $131.79 and its two-hundred day moving average price is $133.33.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.05. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The firm had revenue of $668.00 million for the quarter, compared to analysts’ expectations of $674.08 million. During the same period in the previous year, the company posted $1.53 EPS. The company’s quarterly revenue was up 14.1% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories Intl. will post 6.55 EPS for the current fiscal year.

In other news, VP Birgit Girshick sold 1,499 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $137.23, for a total transaction of $205,707.77. Following the completion of the transaction, the vice president now owns 25,459 shares of the company’s stock, valued at $3,493,738.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.80% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Squar Milner Financial Services LLC increased its stake in Charles River Laboratories Intl. by 253.2% in the third quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 157 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in Charles River Laboratories Intl. in the third quarter valued at about $33,000. Flagship Harbor Advisors LLC increased its stake in Charles River Laboratories Intl. by 132.1% in the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 181 shares during the period. CWM LLC grew its stake in Charles River Laboratories Intl. by 75.9% during the third quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after buying an additional 167 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in Charles River Laboratories Intl. during the second quarter worth about $69,000. 94.45% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What is the Hang Seng index?  

Stock Target Advisor

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Leave a Reply

Your email address will not be published. Required fields are marked *

*